Ernexa Therapeutics Inc. Common Stock (ERNA)

About ERNA

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rhe…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

5

Website

www.ernexatx.com/

Fundamentals

1-day range

$4.57$4.99

Market cap

$4.02M

P/E (trailing)

—

P/E (forward)

-0.48

EPS (trailing)

$-25.77

Dividend yield

—

Beta

2.63

Avg. volume

480.1K

Forecasts

1 analyst ratings

Ernexa Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $4.57

  ▼ 4.99%
  Market cap $4.02MP/E —
  $3.18$71.5
• REVB

  Revelation Biosciences Inc. Common Stock

  $1.05

  ▲ 1.94%
  Market cap $3.99MP/E 0.04
  $0.875$11.6
• RDHL

  Redhill Biopharma Ltd. American Depositary Shares

  $0.6899

  ▲ 9.51%
  Market cap $3.95MP/E —
  $0.57$2.79
• INM

  InMed Pharmaceuticals Inc. Common Shares

  $1.43

  ▼ 0.35%
  Market cap $4.09MP/E —
  $0.575$2.5
• MBIO

  Mustang Bio Inc. Common Stock

  $0.5375

  ▼ 2.27%
  Market cap $3.88MP/E —
  $0.525$1.85
• ZSTK

  ZeroStack Corp. Common Stock

  $5.51

  ▼ 6.29%
  Market cap $4.21MP/E —
  $1.32$47
• XRTX

  XORTX Therapeutics Inc. Common Shares

  $2.34

  ▼ 4.18%
  Market cap $3.69MP/E —
  $2.42$9.85

P/E shows — for peers not currently carrying a live signal of their own.